{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:33:55Z","timestamp":1793504035312,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Pharma KK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Poor persistence with glaucoma therapy can lead to disease progression and subsequent blindness. Persistence with second-line glaucoma combination treatment in a Japanese real-world setting and whether it differed from fixed and unfixed combination drugs was investigated.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This was a retrospective, non-interventional, cohort study using data from a Japanese medical claims database. Patients with glaucoma aged \u226520\u2009years with a first drug claim for glaucoma treatment between 01 July 2005 and 30 October 2014 and with data for &gt;\u20096\u2009months before and after this first prescription were included. The primary endpoint was duration of drug persistence among glaucoma patients with and without the use of fixed combination drugs in the year following initiation of second-line combination treatment.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Of 1403 patients included in the analysis, 364 (25.94%) received fixed combination drugs and 1039 (74.06%) received unfixed combination drugs as second-line treatment. Baseline characteristics were generally comparable between the groups. A total of 39.01% of patients on fixed combination drugs, compared with 41.67% of patients on unfixed combination drugs, persisted on their glaucoma drugs 12\u2009months post second-index date. Median persistence durations for the fixed combination drugs and unfixed combination drugs groups were 6 (95% confidence interval [CI]: 5\u20138) and 7\u2009months (95% CI 6\u20139), respectively. Patients who received prostaglandin analogs (PGAs) were the most persistent with their treatment (<jats:italic>n<\/jats:italic>\u2009=\u200999, 12.84%). Patients diagnosed with primary open-angle glaucoma were less likely to experience treatment modification (hazard ratio [HR]: 0.800, 95% CI 0.649\u20130.986, <jats:italic>P<\/jats:italic>\u2009=\u20090.036), while those diagnosed with secondary glaucoma were more likely to experience treatment modification (HR: 1.678, 95% CI 1.231\u20132.288, <jats:italic>P<\/jats:italic>\u2009=\u20090.001) compared with glaucoma suspects.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In this retrospective claims database study, the persistence rate of second-line glaucoma combination treatment was low, with no difference in persistence between glaucoma patients receiving unfixed combination drugs compared with fixed combination drugs. Patients on PGA showed greater persistence rates compared with other treatments.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12886-020-01508-8","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T14:02:53Z","timestamp":1591797773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Persistence and treatment patterns of fixed combination drugs for glaucoma: a retrospective claims database study in Japan"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8506-8503","authenticated-orcid":false,"given":"Kenji","family":"Kashiwagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Chono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Koesters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poh Sin","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"issue":"1","key":"1508_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.mjafi.2015.12.001","volume":"72","author":"MGJKS Parihar","year":"2016","unstructured":"Parihar MGJKS. Glaucoma: the \u201cblack hole\u201d of irreversible blindness. Med J Armed Forces India. 2016;72(1):3\u20134.","journal-title":"Med J Armed Forces India"},{"issue":"4","key":"1508_CR2","first-page":"598","volume":"140","author":"BL Nordstrom","year":"2005","unstructured":"Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Clin Nutr. 2005;140(4):598\u2013606.","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"1508_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2217\/nmt-2017-0004","volume":"7","author":"G Jutley","year":"2017","unstructured":"Jutley G, Luk SMH, Dehabadi MH, Francesca M. Management of glaucoma as a neurodegenerative disease. Neurodegener Dis Manag. 2017;7(2):157\u201372.","journal-title":"Neurodegener Dis Manag"},{"key":"1508_CR4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2147\/PPA.S23780","volume":"5","author":"G Reardon","year":"2011","unstructured":"Reardon G, Kotak S, Schwartz GF. Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence. 2011;5:441\u201363.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"1508_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2165\/11539460-000000000-00000","volume":"4","author":"M Iskedjian","year":"2011","unstructured":"Iskedjian M, Covert DW, Walker JH. Persistence with prostaglandin agonist use with and without adjunctive therapy for glaucoma patients. Patient. 2011;4(2):133\u201341.","journal-title":"Patient."},{"issue":"1","key":"1508_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s10384-013-0284-2","volume":"58","author":"K Kashiwagi","year":"2014","unstructured":"Kashiwagi K, Furuya T. Persistence with topical glaucoma therapy among newly diagnosed Japanese patients. Jpn J Ophthalmol. 2014;58(1):68\u201374.","journal-title":"Jpn J Ophthalmol"},{"key":"1508_CR7","volume-title":"Glaucoma treatment guideline","author":"Japanese Glaucoma Society","year":"2018","unstructured":"Japanese Glaucoma Society. Glaucoma treatment guideline. 4th ed; 2018.","edition":"4"},{"issue":"2","key":"1508_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/tcrm.2006.2.2.193","volume":"2","author":"RJ Noecker","year":"2006","unstructured":"Noecker RJ. The management of glaucoma and intraocular hypertension: current approaches and recent advances. Ther Clin Risk Manag. 2006;2(2):193\u2013206.","journal-title":"Ther Clin Risk Manag"},{"issue":"8","key":"1508_CR9","doi-asserted-by":"publisher","first-page":"e720","DOI":"10.1111\/aos.13401","volume":"95","author":"M Aihara","year":"2017","unstructured":"Aihara M, Adachi M, Matsuo H, Togano T, Fukuchi T, Sasaki N. Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin-treated glaucoma patients. Acta Ophthalmol. 2017;95(8):e720\u20136.","journal-title":"Acta Ophthalmol"},{"issue":"9","key":"1508_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045079","volume":"7","author":"J Cheng","year":"2012","unstructured":"Cheng J, Cheng S, Gao L, Lu G, Wei R. Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS One. 2012;7(9):e45079.","journal-title":"PLoS One"},{"issue":"1","key":"1508_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/IJG.0000000000000081","volume":"24","author":"VC Leung","year":"2015","unstructured":"Leung VC, Jin Y-P, Hatch W, Mammo Z, Trope GE, Buys YM, et al. The relationship between sociodemographic factors and persistence with topical glaucoma medications. J Glaucoma. 2015;24(1):69\u201376.","journal-title":"J Glaucoma"},{"issue":"5","key":"1508_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/archophthalmol.2010.345","volume":"129","author":"DT Quek","year":"2011","unstructured":"Quek DT, Ong G-T, Perera SA, Lamoureux EL, Aung T. Persistence of patients receiving topical glaucoma monotherapy in an Asian population. Arch Ophthalmol. 2011;129(5):643\u20138.","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"1508_CR13","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1001\/jamaophthalmol.2014.3333","volume":"132","author":"D-K Hwang","year":"2014","unstructured":"Hwang D-K, Liu CJ-L, Pu C-Y, Chou Y-J, Chou P. Persistence of topical glaucoma medication a nationwide population-based cohort study in Taiwan. JAMA Ophthalmol. 2014;132(12):1446\u201352.","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"1508_CR14","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/j.ophtha.2009.06.026","volume":"116","author":"DS Friedman","year":"2009","unstructured":"Friedman DS. Introduction: new insights on enhancing adherence to topical glaucoma. Ophthalmology. 2009;116(11):S29.","journal-title":"Ophthalmology."},{"issue":"7","key":"1508_CR15","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.ophtha.2015.03.026","volume":"122","author":"PA Newman-Casey","year":"2015","unstructured":"Newman-Casey PA, Robin AL, Blachley T, Farris K, Heisler M, Resnicow K, et al. The Most common barriers to Glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122(7):1308\u201316.","journal-title":"Ophthalmology."},{"issue":"1","key":"1508_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ophtha.2007.01.036","volume":"115","author":"C Baudouin","year":"2008","unstructured":"Baudouin C, Liang H, Hamard P, Riancho L, Creuzot-Garcher C, Warnet JM, et al. The ocular surface of Glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology. 2008;115(1):109\u201315.","journal-title":"Ophthalmology."},{"issue":"1","key":"1508_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2011.05.033","volume":"153","author":"SE Skalicky","year":"2012","unstructured":"Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153(1):1\u20139.","journal-title":"Am J Ophthalmol"},{"key":"1508_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ajo.2016.12.002","volume":"176","author":"HS Barnebey","year":"2017","unstructured":"Barnebey HS, Robin AL. Adherence to fixed-combination versus unfixed travoprost 0.004%\/timolol 0.5% for glaucoma or ocular hypertension: A randomized trial. Am J Ophthalmol. 2017;176:61\u20139.","journal-title":"Am J Ophthalmol."},{"key":"1508_CR19","unstructured":"JMDC Inc. JMDC claim database 2019. https:\/\/www.jmdc.co.jp\/en\/pharma\/database.html. Accessed 6 May 2019."},{"issue":"5","key":"1508_CR20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2188\/jea.JE20090066","volume":"20","author":"S Kimura","year":"2010","unstructured":"Kimura S, Sato T, Ikeda S, Noda M, Nakayama T. Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol. 2010;20(5):413\u20139.","journal-title":"J Epidemiol"},{"issue":"10","key":"1508_CR21","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1185\/03007990903260129","volume":"25","author":"EJ Higginbotham","year":"2009","unstructured":"Higginbotham EJ, Hansen J, Davis EJ, Walt JG, Guckian A. Glaucoma medication persistence with a fixed combination versus multiple bottles. Curr Med Res Opin. 2009;25(10):2543\u20137.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"1508_CR22","first-page":"1580","volume":"10","author":"NS Choudhari","year":"2017","unstructured":"Choudhari NS, Pathak-ray V, Kaushik S, Vyas P, George R. Understanding practice patterns of glaucoma sub- specialists in India. Int J Opthalmol. 2017;10(10):1580\u20135.","journal-title":"Int J Opthalmol"},{"issue":"1","key":"1508_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2217\/cer.15.57","volume":"5","author":"AL Coleman","year":"2016","unstructured":"Coleman AL, Lum FC, Su Z, Gliklich RE. Practice patterns and treatment changes for open-angle glaucoma : the RiGOR study. J Comp Eff Res. 2016;5(1):79\u201385.","journal-title":"J Comp Eff Res"},{"issue":"4","key":"1508_CR24","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/IJG.0000000000000380","volume":"25","author":"I Goldshtein","year":"2016","unstructured":"Goldshtein I, Shalev V, Zigman N. The Maccabi glaucoma study: treatment patterns and persistence with glaucoma therapy in a large Israeli health maintenance organization. J Glaucoma. 2016;25(4):386\u201391.","journal-title":"J Glaucoma"},{"issue":"1","key":"1508_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00002512-200522010-00001","volume":"22","author":"RE Marquis","year":"2005","unstructured":"Marquis RE, Whitson JT. Management of glaucoma: focus on pharmacological therapy. Drugs Aging. 2005;22(1):1\u201321.","journal-title":"Drugs Aging"},{"issue":"18","key":"1508_CR26","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1517\/14656566.8.18.3237","volume":"8","author":"JT Whitson","year":"2007","unstructured":"Whitson JT. Glaucoma: a review of adjunctive therapy and new management strategies. Expert Opin Pharmacother. 2007;8(18):3237\u201349.","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"1508_CR27","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1136\/bjophthalmol-2016-308505","volume":"101","author":"CY Kim","year":"2017","unstructured":"Kim CY, Park KH, Ahn J, Ahn M, Cha SC, Kim HS, et al. Treatment patterns and medication adherence of patients with glaucoma in South Korea. Br J Ophthalmol. 2017;101(6):801\u20137.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"1508_CR28","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","volume":"144","author":"AL Robin","year":"2007","unstructured":"Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144(4):533\u201340.","journal-title":"Am J Ophthalmol"},{"key":"1508_CR29","volume-title":"Asia Pacific glaucoma guidelines","author":"Asia-Pacific Glaucoma Society","year":"2016","unstructured":"Asia-Pacific Glaucoma Society. Asia Pacific glaucoma guidelines. 3rd ed; 2016.","edition":"3"},{"issue":"10","key":"1508_CR30","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ajo.2010.05.005","volume":"150","author":"VH Lu","year":"2010","unstructured":"Lu VH, Goldberg I, Lu CY. Use of glaucoma medications: state of the science and directions for observational research. Am J Ophthalmol. 2010;150(10):569\u201374.","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"1508_CR31","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/ncprheum0652","volume":"3","author":"S Suissa","year":"2007","unstructured":"Suissa S, Garbe E. Primer: administrative health databases in observational studies of drug effects \u2014 advantages and disadvantages. Nat Clin Pract. 2007;3(12):725\u201332.","journal-title":"Nat Clin Pract"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01508-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-020-01508-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01508-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T07:46:27Z","timestamp":1625125587000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-020-01508-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1508"],"URL":"https:\/\/doi.org\/10.1186\/s12886-020-01508-8","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,10]]},"assertion":[{"value":"24 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Ethical Review Board of the Specified Nonprofit Organization clinical research promotion network Japan (CR-IRB-0052).This study acquired secondary data from a medical claims database, written informed consent from patients was not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KK has no financial interest to disclose; EC is employee of Novartis Pharma K.K; SK and PSY are employees of Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"223"}}